A Phase 1, Randomized, Two-Period Crossover Study to Evaluate the Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules at Steady State in Healthy Male and Female Subjects
Latest Information Update: 10 Dec 2024
Price :
$35 *
At a glance
- Drugs Nimodipine (Primary) ; Nimodipine
- Indications Subarachnoid haemorrhage
- Focus Pharmacokinetics
- Sponsors Acasti Pharma
- 25 Oct 2024 According to an Acasti Pharma media release, company name Acasti Pharma changed to Grace Therapeutics, Inc.
- 20 Jun 2022 New trial record